科研帝上线啦!115万本专业的英文电子书全部免费下载!

科研帝

 找回密码
 立即注册

手机号码,快捷登录

金币不够用?来这充值VIP学者,无限量下载
查看: 160|回复: 0

Anticoagulants, Antiplatelets, and Thrombolytics (Methods in Molecular Biology)-[1]-[2003]-[djvu]-[Shaker A. Mousa]

[复制链接]
  • TA的每日心情
    开心
    2018-10-7 11:51
  • 签到天数: 68 天

    [LV.6]常住居民II

    23

    主题

    106

    帖子

    222

    积分

    管理员

    Rank: 9Rank: 9Rank: 9

    金币
    1207
    关注领域
    物理学
    QQ
    发表于 2017-11-20 18:05:23 | 显示全部楼层 |阅读模式
    提示:本书回复后可见下载链接(点击链接后等待30秒内会自动启动下载),普通用户回复扣5金币,VIP用户免费下载。还不是VIP?点击这里加入VIP→


    书籍信息:
    标题: Anticoagulants, Antiplatelets, and Thrombolytics (Methods in Molecular Biology)
    语言: English
    格式: djvu
    大小: 2.9M
    页数: 321
    年份: 2003
    作者: Shaker A. Mousa
    版次: 1
    系列: Methods in Molecular Biology
    出版社: Humana Press

    简介

    Albany College of Pharmacy, New York. Highlights the latest developments in antithrombotics and provides experimental methods for the discovery of new and improved anticoagulants. Presents relevant in vitro and in vivo models in thrombosis and hemostasis. For researchers and clinicians. DNLM: Anticoagulants--therapeutic use.


    目录
    Preface......Page 6
    Contents......Page 10
    Contributors......Page 12
    1 Introduction......Page 13
    2.1.2 Procedure......Page 14
    2.2.1 Purpose and Rational......Page 15
    2.2.3 Evaluation......Page 16
    2.3.2 Procedure......Page 17
    2.4.1 Purpose and Rational......Page 18
    2.4.2 Procedure......Page 19
    2.4.5 Modifications of the Method......Page 20
    2.5.2 Procedure......Page 21
    2.6.2 Procedure......Page 22
    2.7.1 Purpose and Rational......Page 23
    2.8.2 Procedure......Page 24
    2.9.2 Procedure......Page 25
    2.10.2 Procedure......Page 26
    2.11.2 Procedure......Page 27
    3 In Vitro Models of Thrombosis......Page 28
    3.1.1 Purpose and Rational......Page 29
    3.1.2 Procedure......Page 30
    3.2.1 Purpose and Rational......Page 31
    3.2.2 Procedure......Page 33
    3.3.1 Purpose and Rational......Page 34
    3.3.2 Procedure......Page 35
    3.3.3 Evaluation......Page 36
    References......Page 38
    1 Introduction......Page 41
    1.2 Models Based on Vessel Wall Damage......Page 43
    1.3.3 Selection of Animal Model......Page 44
    2.1.1 Purpose and Rationale......Page 45
    2.1.2 Procedure......Page 53
    2.1.3 Evaluation......Page 55
    2.1.5 Modifications of the Method......Page 56
    2.2.2 Procedure......Page 57
    2.2.4 Critical Assessment of the Method......Page 58
    2.2.5 Modifications of the Method......Page 59
    2.3 Electrically Induced Thrombosis......Page 60
    2.3.4 Critical Assessment of the Method......Page 64
    2.4 Ferric Chloride (FeCl 3 )-Induced Thrombosis......Page 65
    2.4.2 Procedure......Page 66
    2.5 Thrombin-Induced Clot Formation in Rabbit Femoral or Canine Coronary Artery......Page 67
    2.5.1 Purpose and Rationale......Page 68
    2.6 Laser-Induced Thrombosis......Page 69
    2.6.2 Procedure......Page 70
    2.7.1 Purpose and Rationale......Page 71
    2.8.1 Wire Coil-Induced Thrombosis......Page 72
    2.8.2 Eversion Graft-Induced Thrombosis......Page 74
    2.8.3 Arteriovenous (AV) Shunt Thrombosis......Page 76
    2.8.4 Thread-Induced Venous Thrombosis......Page 77
    2.8.5 Thrombus Formation on Superfused Tendon......Page 78
    2.9.2 Procedure......Page 79
    2.9.5 Modifications of the Method......Page 80
    2.10.1 Purpose and Rationale......Page 81
    2.12.1 Purpose and Rationale......Page 82
    2.13.1 Purpose and Rationale......Page 83
    2.14.2 Procedure......Page 84
    2.14.4 Critical Assessment of the Method......Page 85
    2.15.3 Evaluation......Page 86
    2.16.2 Procedure......Page 87
    3.1.1 Purpose and Rationale......Page 88
    3.2.2 Procedure......Page 89
    3.3.2 Procedure......Page 90
    4.1 Purpose and Rationale......Page 91
    4.1.1 Knock-out Mice......Page 94
    5.2 Evaluation of Bleeding Tendency......Page 100
    5.3 Selection of Models Based on Species-Dependent Pharmacology/ Physiology......Page 101
    5.4 Selection of Models Based on Pharmacokinetics......Page 102
    6 Clinical Relevance of Data Derived from Experimental Models......Page 104
    References......Page 105
    1 Introduction......Page 120
    2 Heparin Versus LMWH......Page 123
    3 Emerging Links Between Thrombosis and Inflammation: Potential Role of Heparin......Page 124
    3.2 Heparin/LMWH and Inflammatory Bowel Diseases......Page 127
    3.3 Heparin as an Anti-inflammatory Molecule: Potential Mechanisms......Page 128
    4 Emerging Links Between Thrombosis and Cancer: Potential Role of Heparin......Page 129
    4.2 Treatment of Venous thromboembolism in Cancer Patients......Page 131
    4.4 Activation of Coagulation in Cancer......Page 133
    4.5 Combination Anticoagulant and Antiplatelet Therapies in Cancer......Page 135
    5 Heparin and Angiogenesis......Page 136
    6 Conclusions......Page 137
    References......Page 138
    1.1 Antibody Generation......Page 144
    1.3 Seroconversion......Page 145
    2.1 Thrombocytopenia......Page 146
    3.1 Antigen Assays......Page 147
    3.2 Functional Assays......Page 149
    3.3.2 HIT Positive Patients......Page 151
    4 Clinical Management......Page 152
    4.1 Direct Thrombin Inhibitors (DTIs)......Page 153
    4.1.1 Argatroban......Page 154
    4.1.2 Lepirudin......Page 155
    4.2.1 Danaparoid......Page 156
    4.3 Vitamin K Antagonists......Page 157
    4.4.2 Multi-Targeted Treatment......Page 158
    5 Regulatory Considerations......Page 159
    6 Summary and Conclusions......Page 160
    References......Page 161
    1 Introduction......Page 168
    2.2 Nematode Anticoagulant Proteins......Page 170
    2.3 Anti-TF/VIIa......Page 172
    2.4 TFPI......Page 173
    3.1 Indirect FXa Inhibitors......Page 174
    3.1.2 SSR126517E (Biotinylated Idraparinux)......Page 175
    3.2.2 Apixaban......Page 176
    3.2.3 Rivaroxaban (Bayer HealthCare AG and J&J/Scios, Inc.)......Page 177
    3.2.5 DU-176b......Page 179
    3.3 Selective, Direct FIXa and FXI Inhibitors......Page 180
    4.1 Indirect Thrombin Inhibitors......Page 181
    4.2 Direct Thrombin Inhibitors......Page 182
    4.3.2 Dabigatran......Page 183
    4.3.3 TGN-167......Page 184
    5 Conclusions......Page 185
    References......Page 186
    1 Introduction......Page 191
    1.1 Pharmacology of Warfarin......Page 192
    1.2 Investigating Potential Alternatives to Warfarin......Page 193
    1.3 Safer and More Efficacious Anticoagulation......Page 194
    2 Clinical Pharmacology of Rivaroxaban......Page 195
    2.1 Pharmacokinetics......Page 196
    2.3 Toxicity and Adverse Effects......Page 197
    3 Clinical Indications......Page 198
    4 Post-operative Thromboprophylaxis......Page 199
    5 Treatment of Venous Thrombosis......Page 203
    6.1 Rivaroxaban in ACS......Page 204
    7 Expert Opinion......Page 205
    8 Conclusion......Page 207
    References......Page 208
    1 Introduction......Page 212
    2.1 Heparin and Platelet GPIIa/IIIa Antagonists......Page 216
    2.2.1 Limitations of Combined Therapy......Page 217
    2.2.2 The CLARITY-TIMI Study......Page 218
    2.2.4 The CHARISMA Study......Page 219
    2.2.5 The CURE and PCI-CURE Studies......Page 220
    2.2.6 The MATCH Study......Page 221
    2.2.7 The CARESS Study......Page 222
    2.2.8 Summary: Combination Aspirin and Clopidogrel Therapy......Page 223
    3 Expert Opinion and Future Directions......Page 224
    References......Page 225
    1 Introduction......Page 229
    2.2 Therapeutic Review......Page 231
    3 Conclusion......Page 234
    References......Page 235
    1 Introduction......Page 237
    2.2 Tea Extract......Page 239
    2.4 Echistatin......Page 240
    3.2 Diallyl Trisulfide......Page 241
    4.1 Vitamin E......Page 242
    5.1 Heparin......Page 243
    5.2 Hirudin......Page 244
    References......Page 245
    1.1 Coagulation Activation in Cancer......Page 249
    1.2 The Role of Tissue Factor in Cancer-Associated Coagulation Activation......Page 250
    1.4 The Role of the Coagulation System in Blood-Borne Metastasis......Page 251
    2.4 Evidence of Clotting Activation......Page 252
    2.5 Quantitation of Pulmonary Tumor Nodules......Page 253
    3.1 Effects of Heparins and Coumadin......Page 254
    3.2 Anti-metastatic Effect of a Non-anticoagulant Low-Molecular Heparin (LMWH) Versus the Standard LMWH Enoxaparin......Page 255
    3.3 The Effect of TF Inhibition on Experimental Metastasis......Page 258
    3.4 Effect of Anti-platelet Agents on Experimental Metastasis......Page 261
    5 Notes......Page 263
    References......Page 265
    1 Introduction......Page 268
    2 Selectins and Anti-selectins......Page 269
    2.1.1 Procedure......Page 270
    3 Integrins......Page 271
    3.1 Potent and Selective Small-Molecule Antagonists of 4 Integrins......Page 272
    3.2.1. Leukocyte Integrin?4?1 as a PotentialTherapeutic Target......Page 273
    3.3. ?2 Integrins......Page 274
    3.4.2 Chronic Therapy with Platelet GPIIb/IIIa Antagonists......Page 275
    4.1 Light Transmittance Aggregometry Assay......Page 276
    4.4. SK-BR-3Cell-Vitronectin(?v?5-Mediated)Adhesion Assay......Page 277
    5 Immunoglobulins......Page 278
    5.3 Human Soluble (s)VCAM-1, ICAM-1, or PECAM Assay......Page 279
    6 Conclusion......Page 280
    References......Page 281
    1 Introduction......Page 284
    2 SNP Mapping......Page 286
    2.1.1 Phase-I Metabolizing Enzymes......Page 288
    2.2 Drug Transporter Gene Polymorphisms......Page 289
    3 Pharmacogenomics of Warfarin Therapy......Page 290
    4 Pharmacogenomics in CVD and Beyond......Page 292
    5 Summary and Future Directions......Page 293
    References......Page 294
    1 Introduction......Page 297
    2 Pathogenesis......Page 298
    2.4 Reperfusion Injury and Nitric Oxide......Page 299
    2.5 Role of Inflammatory Mediators......Page 300
    3.3 Characteristics of Pain......Page 301
    4 Management of Painful Episodes......Page 302
    4.3 Hospitalization......Page 304
    4.7 Rehabilitation and Psychological Considerations in the Management of SCD......Page 306
    5.2 LMWH in Pregnancy and Sickle Cell Anemia......Page 308
    Subject Index......Page 309
    References......Page 310
    SUBJECT INDEX......Page 314

    电子书下载地址回复可见:
    游客,如果您要查看本帖隐藏内容请回复

    每天进步一点点
    回复

    使用道具 举报

    您需要登录后才可以回帖 登录 | 立即注册

    本版积分规则

    关闭

    站长推荐上一条 /1 下一条

    QQ|Archiver|手机版|小黑屋|科研帝   

    GMT+8, 2018-11-21 19:37 , Processed in 0.057600 second(s), 30 queries .

    Powered by Discuz! X3.4

    © 2001-2017 Comsenz Inc.

    快速回复 返回顶部 返回列表